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The ability of Staphylococcus aureus to clot plasma through conformational activation of prothrombin by
staphylocoagulase is used to distinguish S. aureus from coagulase-negative staphylococci. We show that while
the direct thrombin inhibitor dabigatran inhibits staphylocoagulase activity, the clinical use of dabigatran
etexilate is not expected to interfere with direct tube coagulase testing.
Since the early notion, developed more than a century ago,
that the ability to clot plasma correlates with the pathogenic
potential of staphylococci (3, 14), this phenomenon has been
used to distinguish Staphylococcus aureus from less virulent,
coagulase-negative staphylococci. Although the use of new mo-
lecular methods for rapid identification of S. aureus from blood
culture bottles is expanding (15, 17), detection of coagulase
activity by direct tube coagulase (DTC) testing remains a cost-
effective, easy to perform, and reliable method for early detec-
tion of S. aureus in blood culture broth with a Gram stain result
suggestive of staphylococci (10, 13, 16, 23). Since false-negative
results increase the therapeutic delay, the carryover of contam-
inants from either the culture broth or the patient’s plasma
that interfere with the tube test clotting reaction has to be
avoided (23).
Clotting occurs when fibrinogen is converted into fibrin by
thrombin. Under physiological conditions, the proteolytic
activation of the inactive precursor prothrombin into throm-
bin is the final step in the tightly regulated coagulation
cascade. Staphylocoagulase secreted by S. aureus directly binds
to prothrombin to form the staphylothrombin complex and
thus bypasses the coagulation cascade and its physiological
regulation (6). As a consequence of this unique nonproteolytic
direct thrombin activation, treatment with heparins, vitamin K
antagonists, or the thrombin inhibitor hirudin does not inter-
fere with staphylothrombin function (9) and is of no concern
for DTC testing.
In view of the recent availability and increasing clinical use
of the new direct thrombin inhibitor dabigatran etexilate, we
studied whether dabigatran inhibits staphylocoagulase and
whether clinical use of dabigatran etexilate is expected to in-
terfere with DTC testing.
To test these possibilities, we measured coagulation of cit-
rated human plasma as the change in absorbance at 405 nm
(A405) after the addition of purified staphylocoagulase (3 nM)
in the presence of increasing concentrations (0, 0.625, 1.25,
2.5, 5, and 10 nM) of dabigatran (Boehringer Ingelheim
Pharma GmbH & Co. KG, Biberach, Germany). Coagulase
(Synapse BV, Maastricht, Netherlands) was purified over a
bovine thrombin column as described elsewhere (2). To com-
pare the pharmacokinetics of the inhibition of activated human
thrombin and the staphylothrombin complex, we added the
chromogene substrate Biophen CS-01(38) (Hyphen BioMed,
Neuville-sur-Oise, France) to microwells containing dabigat-
ran and either purified human alpha-thrombin (Enzyme Re-
search Laboratories, Swansea, United Kingdom) or a mixture
of staphylocoagulase and purified human prothrombin (En-
zyme Research Laboratories, Swansea, United Kingdom). We
measured the maximum substrate conversion rate (change in
A405) in the presence of a range of dabigatran concentrations
(0, 100, 200, 400, 800, and 1,600 nM) at 4 different substrate
concentrations (100, 200, 400, and 800 M) and determined
the Kis of dabigatran for both alpha-thrombin and the
staphylothrombin complex from the resulting substrate-ve-
locity curves.
To evaluate the effect of dabigatran on tube coagulase test-
ing, we obtained 25 consecutive blood culture samples in BacT/
Alert bottles (bioMe´rieux) that had tested positive for S. au-
reus from the University of Leuven hospital laboratory. DTC
testing was performed as follows: we mixed 100 l of the
culture broth with 300 l of EDTA-treated rabbit plasma (Re-
mel, Lenexa, KS), which is used routinely as a coagulase tube
test reagent and had been spiked with dabigatran (final con-
centrations of 200, 100, 50, 25, 12.5, and 6.25 nM), and assessed
clotting after 1, 2, and 4 h of aerobic incubation at 37°C.
In order to further determine the impact of the clinical use
of dabigatran etexilate on DTC testing in routine practice, we
inoculated 12 aerobic blood culture bottles (BacT/Alert; bio-
Me´rieux) containing either 10 ml of citrated blood (6 bottles)
or 10 ml of blood spiked with dabigatran (concentration in
plasma, 400 nM; 6 bottles) with a small inoculum of a refer-
ence S. aureus strain (ATCC 25923). After inoculation, the
culture bottles were incubated in an automated BacT/Alert
three-dimensional microbial detection system (bioMe´rieux).
When culture samples were detected to be positive, 5 separate
DTC tests for each culture bottle were performed by mixing
100 l of culture broth with 300 l of rabbit plasma (Remel,
Lenexa, KS) and assessing coagulation after 1, 2, and 4 h of
aerobic incubation.
We found that dabigatran delays clotting of human plasma
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by staphylothrombin (3 nM) in a concentration-dependent
way, with a 50% inhibitory concentration (IC50) of 2.3 nM
(95% confidence interval [CI], 1.2 to 4.5 nM) as illustrated in
Fig. 1. Dabigatran inhibited the amidase activities of staphylo-
thrombin and alpha-thrombin to comparable extents, with Kis
in the low nanomolar range (means  standard errors of the
means [SEM], 8.6  1.3 nM for staphylothrombin and 10.9 
1.6 nM for alpha-thrombin).
In the DTC testing, all 25 clinical S. aureus strains tested
showed clotting at the final readout (4 h) in the absence of
dabigatran. Dabigatran concentrations above 100 nM delayed
positivity for more than half of all tested tubes, and 5 tubes
(20%) remained falsely negative after 4 h. The lowest concen-
tration of dabigatran tested, 6.25 nM, did not influence the
result of the tube testing at any time point. At 12.5 to 25 nM,
dabigatran did not have an impact on the final readout at 4 h
but clotting was delayed to later time points in a number of test
tubes (Table 1).
To directly study the effect of dabigatran carryover on DTC
testing, we inoculated a reference S. aureus strain into blood
culture bottles to which we added 10 ml of blood with (n  6)
or without (n  6) dabigatran. After 1 h, there was no sign of
clotting in any of the tubes. After 2 h, all tubes showed partial
clotting, and samples in all tubes were firmly clotted after 4 h.
There were no differences between culture bottles with and
without dabigatran.
Our results demonstrate that the direct thrombin inhibitor
dabigatran effectively inhibits the staphylothrombin-induced
clotting of human plasma. These findings are in agreement
with the observation of Hijikata-Okunomiya and Kataoka, who
previously showed that the thrombin inhibitor argatroban in-
hibits staphylothrombin (11). In contrast with argatroban, how-
ever, which has rather limited clinical use (25), dabigatran
etexilate, the prodrug of dabigatran, has been approved for
prevention of venous thromboembolism following orthopedic
surgery (5) and has been successfully tested in phase III studies
in the treatment of venous thromboembolism (19) and in the
prevention of stroke in cases of atrial fibrillation (4). As a
growing number of patients are likely to be treated with this
new drug in the near future, the question arises of whether
clinical use of dabigatran etexilate will interfere with DTC
testing.
Our data demonstrate that dabigatran indeed inhibits the
clotting of rabbit plasma induced by staphylocoagulase in a
time- and concentration-dependent way and that this inhibi-
tion can result in false-negative or delayed-positive tube test
readouts. However, dabigatran concentrations of 25 nM and
below in a test tube did not affect the final readout in our
experiments. Clinically relevant peak concentrations of dabig-
atran in plasma are 180 ng/ml (350 nM) (21, 22). For DTC
testing, the patient blood sample is first diluted 1/5 in the blood
culture medium and then diluted again 1/3 to 1/4 when the
culture broth is added to the rabbit plasma. Thus, considering
that the blood sample is diluted a minimum of 1/15 in the test
tube, dabigatran concentrations in the clinical setting are ex-
pected to be well below this 25 nM threshold and the clinical
use of dabigatran etexilate is not expected to affect the readout
after 4 h according to our observations.
To confirm this, we inoculated blood with a supratherapeu-
tic dabigatran concentration (400 nM) and a reference S. au-
reus strain and performed standard DTC testing when the
culture bottles were detected as positive. Despite the high
dabigatran concentration used, there was no change in the
coagulase test readouts compared to those for the control
culture bottles without dabigatran. Taken together, our data
show that while dabigatran inhibits staphylothrombin at clini-
cally relevant concentrations in plasma, concentrations ob-
tained after dilution in blood culture broth and coagulase re-
agent do not affect DTC testing.
The availability of a pharmacological staphylothrombin in-
hibitor could facilitate further research on the controversial
role of staphylocoagulase in the pathogenesis of S. aureus in-
fections. Although staphylocoagulase is classically considered
to be a virulence factor, the available evidence from animal
infection models is conflicting. Some studies showed decreased
virulence of coagulase-negative mutants (1, 7, 8, 12, 20), but
these mutant strains arose from nonspecific increased mu-
tagenesis and probably had inherently reduced virulence
compared to the nonmutant parent strain. Coagulase-nega-
tive mutants obtained by site-specific mutagenesis showed
reduced virulence in a murine hematogenous pulmonary
infection model (18), and inhibition of coagulase activity using
inhibitory RNA reduced bacterial loads in an animal S. aureus
bacteremia model (24), showing the potential of coagulase
inhibition strategies in these settings. However, such studies
either require the use of mutant strains or involve laborious
TABLE 1. Effect of dabigatran on direct tube coagulase testinga
Concn of
dabigatran (nM)
No. (%) of false-negative tube test readouts
(n  25) at:
1 h 2 h 4 h
200 13 (52) 15 (60) 8 (32)
100 13 (52) 13 (52) 7 (28)
50 8 (32) 6 (24) 1 (4)
25 2 (8) 2 (8) 0 (0)
12.5 1 (4) 2 (8) 0 (0)
6.25 0 (0) 0 (0) 0 (0)
a The table shows numbers and percentages of direct tube coagulase tests
with a negative readout as opposed to a positive control for a range of
dabigatran concentrations. Results are shown for readouts at 1, 2, and 4 h for
all tubes (n  25).
FIG. 1. Dabigatran inhibits clotting of human plasma induced by
staphylocoagulase (3 nM) in a concentration-dependent manner. Data
are expressed as means  SEM (n  8).
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strategies to inhibit coagulase activity that are not applicable in
a clinical setting.
In conclusion, we show that dabigatran is a potent inhibitor
of staphylothrombin, offering new opportunities to study the
role of staphylocoagulase as a virulence factor and the impact
of its inhibition in S. aureus clinical infections. Although dabig-
atran also inhibits the clotting of rabbit plasma by staphylo-
thrombin, its expanding clinical use is not anticipated to be of
concern for diagnostic tube testing.
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